17:25 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF could help treat KRAS- and p53-mutant pancreatic ductal adenocarcinoma (PDAC). In nine patient-derived KRAS- and p53-mutant PDAC...
18:05 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Lilly looks to expand Cyramza's label into first-line NSCLC

Eli Lilly said it plans to initiate global regulatory applications mid-year seeking to expand the label of Cyramza ramucirumab to include first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have activating...
19:18 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Dec. 11 with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant...
13:05 , Dec 11, 2018 |  BC Extra  |  Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Tuesday with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant oncogenes...
13:03 , Dec 11, 2018 |  BC Innovations  |  Emerging Company Profile

Black Diamond: Mapping allostery

Black Diamond Therapeutics Inc. emerged from stealth on Tuesday with a platform to mine and drug baskets of allosteric mutant oncogenes using troves of human sequencing data that contain non-catalytic mutations previously deemed non-actionable. The...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
19:37 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a...
20:34 , Aug 17, 2018 |  BC Extra  |  Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
22:54 , Jun 20, 2018 |  BC Extra  |  Preclinical News

Broad ErbB inhibition arrests KRAS mutant cancer

Multi-ErbB inhibitors may provide a treatment option for K-Ras (KRAS)-driven lung cancer where ErbB family member EGFR1-specific therapies have failed, according to two studies published in Science Translational Medicine on Wednesday. The findings suggest a...
18:21 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer, sarcoma Cell culture studies suggest inhibiting IFT88 or SCLT1 could help treat kinase inhibitor-resistant lung cancer and rhabdomyosarcoma. In a human EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) cell line, the EGFR...